Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

[1]  G. Dong,et al.  Journey to the east: Diverse routes and variable flowering times for wheat and barley en route to prehistoric China , 2017, PloS one.

[2]  Y. Chern,et al.  The type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA/STAT3-dependent pathway , 2017, Journal of Biomedical Science.

[3]  Bin-hui Ren,et al.  Age is associated with prognosis in serous ovarian carcinoma , 2017, Journal of Ovarian Research.

[4]  Ping Wang,et al.  Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis , 2017, PloS one.

[5]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[6]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[7]  Tasuku Honjo,et al.  Cancer immunotherapies targeting the PD-1 signaling pathway , 2017, Journal of Biomedical Science.

[8]  J. Lang,et al.  Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer , 2017, Journal of gynecologic oncology.

[9]  E. Richardsen,et al.  Assessing PDL‐1 and PD‐1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach , 2017, Clinical lung cancer.

[10]  H. Ishwaran,et al.  Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade , 2016, Cell.

[11]  B. Monk,et al.  The role of immune checkpoint inhibition in the treatment of ovarian cancer , 2016, Gynecologic Oncology Research and Practice.

[12]  T. Curiel,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  I. Konishi,et al.  Immune checkpoint inhibition in ovarian cancer. , 2016, International immunology.

[14]  Jody M. Webster,et al.  Erratum: Intensification of the meridional temperature gradient in the Great Barrier Reef following the Last Glacial Maximum (Nature Communications (2014) 5 (4102) DOI: 10.1038/ncomms5102) , 2016 .

[15]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[16]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American journal of clinical oncology.

[17]  Y. Xing,et al.  Oncotargets and Therapy Dovepress Prognostic Value of Programmed Cell Death-ligand 1 Expression in Patients with Non-small-cell Lung Cancer: Evidence from an Updated Meta-analysis , 2022 .

[18]  C. Denkert,et al.  Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma , 2015, Oncotarget.

[19]  S. Grupp,et al.  Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells , 2015, Journal of Immunotherapy for Cancer.

[20]  J. Duan,et al.  Corrigendum: Frankincense and myrrh suppress inflammation via regulation of the metabolic profiling and the MAPK signaling pathway , 2015, Scientific Reports.

[21]  Bin Shang,et al.  Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis , 2015, Scientific Reports.

[22]  M. Johnson,et al.  Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study , 2015, PloS one.

[23]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[24]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Wardelmann,et al.  PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups , 2015, PloS one.

[26]  Pier Luigi Lopalco,et al.  Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV , 2015, Journal of immunology research.

[27]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[28]  C. Marchetti,et al.  Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors , 2015, Journal of immunology research.

[29]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[30]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[31]  H. Kohrt,et al.  Immunotherapeutic approaches to ovarian cancer treatment , 2015, Journal of Immunotherapy for Cancer.

[32]  M. Azuma,et al.  Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. , 2015, Oral oncology.

[33]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[34]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[35]  J. Ledermann,et al.  Treatment options in recurrent ovarian cancer: latest evidence and clinical potential , 2014, Therapeutic advances in medical oncology.

[36]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[37]  S. Ghaem-Maghami,et al.  Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer , 2014, Cancer Immunology, Immunotherapy.

[38]  W. Gillanders,et al.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer , 2013, Breast Cancer Research and Treatment.

[39]  N. Matsumura,et al.  PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction , 2013, Clinical Cancer Research.

[40]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[41]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[42]  M. Sznol,et al.  Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy , 2011, The Yale journal of biology and medicine.

[43]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[44]  C. Figdor,et al.  Ovarian cancer creates a suppressive microenvironment to escape immune elimination. , 2010, Gynecologic oncology.

[45]  S. Quezada,et al.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.

[46]  J. Bayry.  Autoimmunity: CTLA-4: a key protein in autoimmunity , 2009, Nature Reviews Rheumatology.

[47]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[48]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[49]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[50]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[51]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[52]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[53]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[54]  H. C. Nauts,et al.  The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. , 1946, Cancer research.

[55]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[56]  김세익.  Development of the short version of the Gynecologic Cancer Lymphedema Questionnaire: GCLQ-7 , 2017 .

[57]  Patrice Ravel,et al.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.

[58]  E. McCarthy.  The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. , 2006, The Iowa orthopaedic journal.

[59]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.